JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.29 CNY | +1.09% |
|
+4.97% | -16.61% |
| 29/04 | Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 09/04 | Lianhuan Pharma Obtains China Registration Approval for Antihistamine | MT |
| Sales 2022 | 1.96B 270M 22.51B | Sales 2023 | 2.17B 300M 25.03B | Capitalization | 3.18B 439M 36.61B |
|---|---|---|---|---|---|
| Net income 2022 | 141M 19.48M 1.62B | Net income 2023 | 135M 18.65M 1.55B | EV / Sales 2022 | 1.56 x |
| Net Debt 2022 | 359M 49.59M 4.13B | Net Debt 2023 | 424M 58.62M 4.89B | EV / Sales 2023 | 1.66 x |
| P/E ratio 2022 |
19.2
x | P/E ratio 2023 |
23.7
x | Employees | 1,296 |
| Yield 2022 |
1.6% | Yield 2023 |
1.35% | Free-Float | 57.53% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.09% | ||
| 1 week | +4.97% | ||
| 1 month | +0.11% | ||
| 3 months | +15.12% | ||
| 6 months | -8.83% | ||
| Current year | -16.61% |
1 week
8.91
9.45
1 month
8.109.45
Current year
6.7111.33
1 year
6.7114.40
3 years
6.7114.40
5 years
6.3223.30
10 years
5.5224.75
| Managers | Title | Age | Since |
|---|---|---|---|
Ben Niu
CEO | Chief Executive Officer | 43 | 22/20/22 |
Wen Ge Wu
CHM | Chairman | 56 | 17/14/17 |
He Ping Pan
DFI | Director of Finance/CFO | 60 | 19/09/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
He Ping Pan
DFI | Director of Finance/CFO | 60 | 19/09/19 |
Bin Zhang
BRD | Director/Board Member | 56 | 22/20/22 |
Guang Ji Wang
BRD | Director/Board Member | 71 | 22/18/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 9.29 | +1.09% | 9,766,200 |
| 29/24/29 | 9.19 | +3.26% | 5,661,882 |
| 26/24/26 | 8.9 | +0.56% | 5,207,877 |
| 25/24/25 | 8.85 | +2.08% | 5,139,290 |
| 24/24/24 | 8.67 | +1.29% | 4,661,900 |
End-of-day quote Shanghai S.E., April 30, 2024
More quotes
Jiangsu Lianhuan Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, production and sales of chemical medicines. The Company's products are mainly applied as urinary system medicines, antihistamines and cardiovascular medicines. The Company's products include Epristeride Tablets, Ebastine Tablets, Felodipine Tablets, Felodipine Sustained Release Capsules, Simvastatin Tablets, Lumbrokinase Capsulesand and Balofloxacin Tablets. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -16.61% | 366M | |
| +26.14% | 681B | |
| +21.85% | 556B | |
| -5.26% | 361B | |
| +17.34% | 325B | |
| +4.83% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -4.20% | 157B |
- Stock Market
- Equities
- 600513 Stock
